Literature DB >> 20042050

Diabetic rats and mice are resistant to porcine and human insulin: flawed experimental models for testing islet xenografts.

Andrew R Pepper1, Chris Gall, Delfina M Mazzuca, Christopher William James Melling, David J G White.   

Abstract

BACKGROUND: Islet transplantation is potentially a promising therapy for the restoration of carbohydrate control to diabetic patients. However, the global application of islet transplantation requires a ubiquitous source of beta cells. The xenotransplantation of porcine islets would provide such a source. Success in porcine islet xenografting has been achieved in diabetic primates. However, there are few reports of reversal of diabetes with porcine islet xenografts in rodent models of diabetes, relative to the number of successful rodent experiments performed as allografts. Here we report for the first time the inability of porcine (and human) insulin to control blood glucose levels in diabetic rodents determined by a series of dose escalating studies.
METHODS: Insulin was administered intravenously to streptozotocin induced diabetic Lewis rats, Balb/c and athymic Balb/c mice (n = 5 per group) at the following doses: Group I "physiological dose" (pd) of 0.16 U/kg for a total dose of 40 mU to a 250 g rat. Group II received 0.64 U/kg (4xpd), group III 1.6 U/kg (10xpd) and group IV 6.4 U/kg (40xpd). Blood glucose levels were monitored in each animal at seven time points: 0 (pre-injection), 10 min, 20 min, 30 min, 45 min, 1 h, 1.5 h, 2 h and 3 h post-injection. Serum insulin levels were also determined.
RESULTS: Diabetic Lewis rats achieved a maximum reduction in blood glucose from 22.1 +/- 1.8mmol/l to 8.0 +/- 3.1 mmol/l (a 63.7% reduction), 90 minutes post-injection of 6.4 U/kg dose of porcine insulin (40xpd). Human insulin was less effective at reducing blood glucose levels in rats than porcine insulin (P < 0.001). Porcine insulin reduced blood glucose levels in Balb/c mice from a mean of 18.2 +/- 2.1 mmol/l to a hypoglycemic minimum of 1.26 +/- 0.18 mmol/l a reduction of 93.0%, 60 min post-injection of the maximum dose of 6.4 U/kg. Balb/c mice were significantly more responsive to porcine insulin than Lewis rats at doses of 0.64 U/kg (P < 0.001), 1.6 U/kg (P < 0.05) and 6.4 U/kg (P < 0.001). Athymic Balb/c nude mice reached a maximum reduction in blood glucose from 21.6 +/- 1.8 mmol/l to 3.6 +/- 0.9 mmol/l (a 83.4% reduction) 120 min post-injection at a dose of 6.4 U/kg. Overall, athymic Balb/c nude mice were more resistant to porcine insulin than immunocompetent Balb/c mice at doses of 0.64 U/kg (P < 0.001), 1.6 U/kg (P < 0.001) and 6.4 U/kg (P < 0.05). Insulin diluent alone marginally increased blood glucose levels in all animals tested.
CONCLUSIONS: Our results suggest that restoration of normoglycemia in diabetic rodents is not ideal for testing porcine islets xenografts since the reversals of diabetes in these species requires 20 to 40 times the dose of porcine insulin used in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042050     DOI: 10.1111/j.1399-3089.2009.00548.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  9 in total

1.  Therapeutic effects of a non-β cell bioartificial pancreas in diabetic mice.

Authors:  Aubrey R Tiernan; Peter M Thulé; Athanassios Sambanis
Journal:  Transplantation       Date:  2014-09-15       Impact factor: 4.939

Review 2.  Porcine Islet Xenografts: a Clinical Source of ß-Cell Grafts.

Authors:  Bassem F Salama; Gregory S Korbutt
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

3.  Delivery of a therapeutic protein by immune-privileged Sertoli cells.

Authors:  Katelyn Halley; Emily L Dyson; Gurvinder Kaur; Payal Mital; Peter M Uong; Brinda Dass; Sherry N Crowell; Jannette M Dufour
Journal:  Cell Transplant       Date:  2010-08-17       Impact factor: 4.064

4.  Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice.

Authors:  Jennifer E Bruin; Alireza Rezania; Jean Xu; Kavitha Narayan; Jessica K Fox; John J O'Neil; Timothy J Kieffer
Journal:  Diabetologia       Date:  2013-06-16       Impact factor: 10.122

5.  Xeno-Transplantation of macro-encapsulated islets and Pluripotent Stem Cell-Derived Pancreatic Progenitors without Immunosuppression.

Authors:  Michael A Bukys; Brandon Bakos; Solomon Afelik; Baruch Zimmerman; Barbara Barbaro; Dan Li Lin; Pilar Vaca; Tali Goldman; Avi Rotem; Margot Damaser; Jose Oberholzer; Uriel Barkai; Jan Jensen
Journal:  J Stem Cell Transplant Biol       Date:  2016-09-21

6.  Sertoli Cells Engineered to Express Insulin to Lower Blood Glucose in Diabetic Mice.

Authors:  Gurvinder Kaur; Lea Ann Thompson; Rachel L Babcock; Karl Mueller; Jannette M Dufour
Journal:  DNA Cell Biol       Date:  2018-06-21       Impact factor: 3.311

7.  Survival of free and encapsulated human and rat islet xenografts transplanted into the mouse bone marrow.

Authors:  Raphael P H Meier; Jörg D Seebach; Philippe Morel; Redouan Mahou; Sophie Borot; Laurianne Giovannoni; Geraldine Parnaud; Elisa Montanari; Domenico Bosco; Christine Wandrey; Thierry Berney; Leo H Bühler; Yannick D Muller
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

8.  Lung-Derived Microscaffolds Facilitate Diabetes Reversal after Mouse and Human Intraperitoneal Islet Transplantation.

Authors:  Nasser Abualhassan; Lena Sapozhnikov; Rena L Pawlick; Meygal Kahana; Andrew R Pepper; Antonio Bruni; Boris Gala-Lopez; Tatsuya Kin; Eduardo Mitrani; A M James Shapiro
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

9.  Accelerated Maturation of Human Stem Cell-Derived Pancreatic Progenitor Cells into Insulin-Secreting Cells in Immunodeficient Rats Relative to Mice.

Authors:  Jennifer E Bruin; Ali Asadi; Jessica K Fox; Suheda Erener; Alireza Rezania; Timothy J Kieffer
Journal:  Stem Cell Reports       Date:  2015-11-19       Impact factor: 7.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.